Navigation Links
IKARIA(R) to In-License BioLineRx's BL-1040
Date:7/6/2009

CLINTON, N.J. and JERUSALEM, July 6 /PRNewswire/ -- Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) today announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx's BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI).

BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair. BL-1040 is the first program to graduate from the BIJ (BioLine Innovations Jerusalem) incubator subsidized by the Israeli Office of the Chief Scientist.

Under the terms of the agreement, BioLineRx will receive upfront and milestone payments. BioLineRx will also receive royalties on annual net sales. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of the Israeli Office of the Chief Scientist.

"The acquisition of the rights to BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ikaria. "Millions of patients suffer from MI each year, and BL-1040 represents the potential of an exciting solution to the problem of ventricular remodeling following AMI, for which the unmet need remains very high."

"This agreement is consistent with our business model of developing early-stage programs through human Proof of Concept trials and ultimately partnering with a global therapeutics company that has the expertise and resources to complete development and commercialization," said Morris C. Laster, M.D., CEO of BioLineRx. "Ikaria's deep and singular focus on therapies for patients
'/>"/>

SOURCE Ikaria Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 SynCardia Systems, ... and only FDA, Health Canada and CE (Europe) approved ... Centre in Scotland, which boasts more than 380,000 visitors ... Heart powered by the Freedom® portable driver as ... the most advanced exhibitions of its kind. , ...
(Date:5/23/2013)... 2013 Ralph Huber, President of PHI ... management products and emergency survival kits would be on ... made at the quarterly executive board meeting on May 22nd. ... silence for the Oklahoma tornado victims and used the opportunity ... their emergency kits is paramount. “When disaster strikes,” he ...
(Date:5/22/2013)... Cambridge Semantics was one of just ... Day” on Capitol Hill, hosted by The Data ... others to showcase how innovative data management applications can address ... (DATA Act). , Originally introduced in 2011 by Committee ... Mark Warner (D-VA ), the DATA Act is ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 ... of regenerative medicine, presented new data generated in collaboration ... (a leading health economics consultancy) demonstrating the significant healthcare ... and venous leg ulcers (VLU) place upon the US ... research, which reveal annual costs of up to $15 ...
Breaking Biology Technology:SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4
... Regenerative Medicine editorial board. , ... Vancouver, BC (PRWEB) ... announced today the appointment of its principle consultant, R. Lee Buckler, ... , , , ,Published by Future Medicine, Regenerative Medicine has become ...
... The inaugural year of The Kavli Prize will be ... Haakon Magnus presenting the prize to the seven Kavli laureates. ... will give lectures throughout the week. , , Note: The award ... be a press briefing at 11.15 AM (CET), September 9, ...
... Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly ... today provided context and additional information,regarding the August 18, ... prior alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies ... as well as others, and previously reported these cases ...
Cached Biology Technology:Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board 2Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 2Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:5/22/2013)... U.S. Forest Service scientists are part of "Landscapes ... the TKF Foundation, will examine how collaborative planning and ... from tragedy. , The TKF Foundation announced today that ... for grant funding. In addition to research on the ... and resiliency, the 3-year, $585,000 grant will contribute to ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... have been shown to adversely affect shell-forming creatures and corals, ... of Oceanography at UC San Diego has shown for the ... in fish. A brief paper published in the June ... in which fish that were exposed to high levels of ...
... the bustling economy of the cell, little bubbles called ... from the port - the cell membrane. Some of ... the cell,s protein factory. Scientists have long believed ... life-supporting nutrients and proteins through an independent process. By ...
... 2009 Scientists at Burnham Institute for Medical Research ... interfere with gene expression) reduce HIV replication and infectivity ... role in controlling the HIV life cycle. The study ... mechanism to help the virus hide from the immune ...
Cached Biology News:High carbon dioxide levels cause abnormally large fish ear bones 2Cells use import machinery to export their goods as well 2Cells use import machinery to export their goods as well 3MicroRNAs help control HIV life cycle 2
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
... sizing single-stranded RNA ranging from 0.5 kb to 10 ... consists of nine bands in even increments (0.5 1 ... to simplify size estimation. The 1.5 kb band is ... and identification of RNA bands on the gel. All ...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Rubeola (Measles) Antigen Preservative: No Preservatives...
Biology Products: